Synergistic composition of pea polypeptide and lactobacillus plantarum and application thereof

Abstract

The invention discloses a synergistic composition of pea polypeptide and lactobacillus plantarum and application of the synergistic composition, and belongs to the technical field of biological medicine. Experiments prove that the lactobacillus plantarum AR342 provided by the invention can effectively inhibit the activity of xanthine oxidase and reduce the level of uric acid in serum, and the AR342 can also improve intestinal flora disorder caused by high uric acid, promote proliferation of beneficial flora and reduce the abundance of harmful flora in intestinal tracts. Meanwhile, it is found that the prepared pea polypeptide can also reduce the content of uric acid, a synergistic composition of the pea polypeptide and the lactobacillus plantarum AR342 also has the activity of inhibiting generation of uric acid in the body, and the effect of the synergistic composition is better than that of independent treatment of the lactobacillus plantarum AR342 or the pea polypeptide. Therefore, the invention provides a new idea for clinical treatment of hyperuricemia.

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to a synergistic composition of pea polypeptide and Lactobacillus plantarum and application thereof. Background Art

[0002] Uric acid is one of the end products of human metabolism. Under normal circumstances, the production and excretion of uric acid are balanced, maintaining a certain level of blood uric acid. When uric acid is produced too much or excreted insufficiently, the blood uric acid level will increase, leading to hyperuricemia. Hyperuricemia is a common metabolic disease that can cause complications such as gout, kidney stones, renal damage, hypertension, and cardiovascular disease. Gout is a typical manifestation of hyperuricemia, an inflammatory joint disease caused by the deposition of urate in the joints and soft tissues. Gout attacks are usually accompanied by severe pain, redness, swelling, heat, and tenderness, which seriously affect the patient's quality of life.

[0003] At present, drugs for the treatment of hyperuricemia and gout are mainly divided into two categories: one is uric acid-lowering drugs, such as allopurinol and benbuquine, which reduce blood uric acid levels by inhibiting the production of uric acid; the other is uricosuric drugs, such as benzenesulfonic acid and probenecid, which reduce the accumulation of uric acid in the body by increasing the excretion of uric acid. However, the use of these drugs has certain limitations and adverse reactions. For example, allopurinol can cause abnormal liver function, gastrointestinal discomfort, rash, etc.; benbuquine can cause renal damage, blood system disorders, allergic reactions, etc.; benzenesulfonic acid can cause gastrointestinal irritation, edema, hypertension, etc.; probenecid can cause kidney stones, renal insufficiency, rash, etc. Therefore, the development of a safe, effective, and side-effect-free uric acid-lowering and anti-gout drug is an urgent need for patients with hyperuricemia and gout.

[0004] In recent years, more and more studies have shown that intestinal flora is closely related to the metabolism of uric acid. The imbalance of intestinal flora can lead to increased production and absorption of uric acid and reduced excretion of uric acid, thereby inducing or aggravating hyperuricemia and gout. Probiotics are a type of active microorganisms that are beneficial to the health of the host. They can regulate the balance of intestinal flora, improve intestinal function, and affect the host's metabolism, immunity and other physiological activities. Food-derived oligopeptides, as a new type of nutritional supplement, are new protein hydrolyzed products made from food protein by enzymatic hydrolysis. Their molecular weight is below 1000Da. Small molecule peptides are easier to be absorbed by the human body than proteins of the same source, and they have good solubility, low viscosity and high utilization rate in the body. In nutrition, it is generally believed that deep-sea fish are high-purine foods, and patients with hyperuricemia should fast. However, studies have found that food-derived oligopeptides extracted from deep-sea fish bonito have the activity of inhibiting xanthine oxidase. Based on this, the present invention provides a synergistic composition of food-derived oligopeptides and Lactobacillus plantarum, which can exert a synergistic effect and significantly inhibit the conversion of purine in the intestine, thereby reducing uric acid levels. Summary of the invention

[0005] The purpose of the present invention is to provide a synergistic composition of pea polypeptide and Lactobacillus plantarum and its application, so as to solve the problems existing in the above-mentioned prior art. The synergistic composition of pea polypeptide and Lactobacillus plantarum provided by the present invention can significantly reduce the level of uric acid, and provides a new idea for the clinical treatment of hyperuricemia.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] The invention provides a strain of Lactobacillus plantarum AR342, wherein the preservation number of the Lactobacillus plantarum AR342 is CGMCC No.27368, the preservation date is May 17, 2023, the preservation unit is the General Microbiology Center of China National Committee for the Preservation of Microorganisms, and the preservation address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing.

[0008] The present invention also provides a synergistic composition of pea polypeptide and Lactobacillus plantarum AR342, wherein the synergistic composition comprises pea polypeptide and Lactobacillus plantarum AR342 in a mass ratio of 1:1;

[0009] The preservation number of the Lactobacillus plantarum AR342 is CGMCC No.27368; the pea polypeptide is obtained by fermenting pea crude protein.

[0010] The present invention also provides a method for preparing the synergistic composition, characterized in that it comprises the step of mixing pea polypeptide with Lactobacillus plantarum AR342.

[0011] Furthermore, the plant lactobacillus AR342 is mixed in the form of a bacterial suspension; the concentration of the plant lactobacillus AR342 bacterial suspension is 1×10 9 cfu / mL.

[0012] Furthermore, the pea polypeptide is prepared by the following steps:

[0013] After mixing pea crude protein and sterile water in a mass volume ratio of (1-2):(1-3), inoculating Aspergillus oryzae BR88 for solid-state fermentation;

[0014] After the fermentation is completed, sterile water is added for homogenization, and the supernatant is collected by centrifugation;

[0015] The supernatant is ultrafiltered, and the filtrate is freeze-dried to obtain pea polypeptide.

[0016] Furthermore, the Aspergillus oryzae BR88 has a deposit number of CGMCC No. 10950, a deposit date of June 3, 2015, a deposit unit of the General Microbiology Center of China National Committee for the Preservation of Microorganisms, a deposit address of No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and an inoculation volume of 5-15% v / m; the fermentation conditions are 25° C. for 30 hours.

[0017] Furthermore, the homogenization treatment time is 5-10 minutes.

[0018] Furthermore, the ultrafiltration is performed continuously through 5000Da and 1000Da membranes.

[0019] The present invention also provides the use of the synergistic composition in preparing a drug for preventing and / or treating hyperuricemia.

[0020] The present invention also provides a medicine for preventing and treating hyperuricemia, comprising the synergistic composition.

[0021] The present invention discloses the following technical effects:

[0022] The plant lactobacillus AR342 provided by the present invention has good acid and bile resistance, can effectively inhibit xanthine oxidase activity, and reduce the level of uric acid in serum; AR342 can significantly reduce the level of renal inflammation caused by high uric acid and alleviate renal cell damage. In addition, AR342 can improve the intestinal flora disorder caused by high uric acid, promote the proliferation of beneficial flora, and reduce the abundance of harmful intestinal flora. At the same time, the present invention found that pea polypeptides can also reduce uric acid content, and the synergistic composition of pea polypeptides and plant lactobacillus AR342 also has the activity of inhibiting uric acid production in the body, and the effect is better than that of plant lactobacillus AR342 or pea polypeptide alone. It can be seen that the present invention provides a new idea for the clinical treatment of hyperuricemia. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0024] Figure 1 The effect of Lactobacillus plantarum AR342 on uric acid content in Example 2; Allopurinol: positive control;

[0025] Figure 2 The effect of Lactobacillus plantarum AR342 on liver XOD activity in Example 2;

[0026] Figure 3 The effect of Lactobacillus plantarum AR342 on kidney in Example 2; the scale bar is 100 μm;

[0027] Figure 4 The effect of Lactobacillus plantarum AR342 on intestinal flora in Example 2; A: composition of intestinal flora of mice in each treatment group; B: statistical chart of Bifidobacterium abundance; C: statistical chart of Akkermansia alkaliphila abundance; Con: control group; Mod: model group;

[0028] Figure 5 The effect of pea polypeptide alone on uric acid content in Example 3; WPP: pea polypeptide, allopurinol: positive control;

[0029] Figure 6 This is the effect of the synergistic treatment of pea polypeptide and Lactobacillus plantarum AR342 on uric acid content in Example 3. DETAILED DESCRIPTION

[0030] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0031] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0032] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0033] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0034] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0035] The present invention screened a strain of Lactobacillus plantarum AR342 that can inhibit uric acid production, and found through experiments that the pea polypeptide prepared by the present invention can also reduce uric acid production, and the effect of the pea polypeptide and Lactobacillus plantarum AR342 synergistic composition is significantly better than the use of either alone. The specific research is as follows.

[0036] Example 1 Isolation, Cultivation and Preservation of Lactobacillus plantarum AR342

[0037] 1. Isolation and purification of bacterial strains

[0038] Fermented vegetable samples were collected from Yili, Xinjiang. 2 g of the sample was cut into pieces and added with 20 mL of sterile water. The mixture was stirred evenly and then graded diluted to obtain a dilution solution. 200 μL of the dilution solution was spread on MRS agar medium and cultured anaerobically at 37°C for 48 h. Strains with different colony morphology were selected and separated by streaking on the MRS agar medium to obtain purified strains.

[0039] 2. Determination of uric acid production rate of each strain

[0040] 2.1 Preparation of bacteria

[0041] The purified single colonies of each strain were picked and inoculated into MRS liquid culture medium, cultured anaerobically at 37°C for 16 h, and centrifuged at 6000 rpm for 5 min to obtain the bacterial cells of each strain, which were then resuspended and washed twice with PBS phosphate buffer and centrifuged at 6000 rpm for 5 min to obtain clean bacterial cells.

[0042] 2.2 Determination of uric acid production rate

[0043] Resuspend each bacterial cell with PBS solution, adjust OD to 1.0, and take 1mL PBS-bacterial suspension. Add 100μL xanthine oxidase (XOD) solution (0.2U / mL) to 1mL PBS-bacterial suspension, incubate at 37℃ for 5min, then centrifuge at 6000rpm for 5min, take 100μL of supernatant in a 96-well plate, add 200μL 20μg / mL xanthine solution, react at 37℃ for 3min in an ELISA reader, measure absorbance at 295nm, and replace fermentation broth with PBS as the control group. The formula for calculating uric acid production rate is:

[0044]

[0045] The results are shown in Table 1. The uric acid production rate of the control group was 85.57%. Among the isolated strains, AR342 had the lowest uric acid production rate of only 44.83%, followed by AR237, with a uric acid production rate of 46.65%.

[0046] Table 1 Uric acid production rate of each strain

[0047]

[0048]

[0049] 3. Identification of bacterial species

[0050] Identification of the AR342 strain with the lowest uric acid production rate.

[0051] The chromosomal DNA of the purified strain AR342 was extracted and colony PCR was performed on 27F / 1492R using 16srDNA universal primers. The 16srDNA sequence was obtained by sequencing after amplification. High homology comparison of bacterial species was performed at NCBI, and the purified strain AR342 was identified as Lactobacillus plantarum.

[0052] Among them, 27F is 5'-AGAGTTTGATCCTGGCTCAG-3' and 1492R is 5'-GGTTACCTTGTTACGACTT-3'.

[0053] The above-mentioned Lactobacillus plantarum AR342 strain was deposited at the General Microbiology Center of China Culture Collection Administration on May 17, 2023. Its deposit number is CGMCC No. 27368, and the deposit address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing.

[0054] Example 2 Lactobacillus plantarum AR342 can alleviate hyperuricemia in mice

[0055] 1. Establishment of hyperuricemia mouse model and experimental grouping

[0056] 1.1 Solution preparation:

[0057] 0.5% (m / v) sodium hydroxymethylcellulose (CMC-Na) suspension: Accurately weigh 0.5 g sodium hydroxymethylcellulose in 100 mL ultrapure water, heat in a water bath after ultrasonication, and stir thoroughly until dissolved.

[0058] Potassium oxonate-adenine-sodium hydroxymethylcellulose suspension: Use 0.5% sodium hydroxymethylcellulose to prepare the suspension, and the mass ratio of potassium oxonate to adenine in the suspension is 2.5:1.

[0059] Allopurinol-hydroxymethylcellulose sodium suspension: Similarly, allopurinol-hydroxymethylcellulose sodium suspension was prepared with 0.5% hydroxymethylcellulose sodium.

[0060] Lactobacillus plantarum AR342 suspension: The AR342 cells collected by centrifugation were washed with physiological saline twice. Then the concentration of the cells was adjusted to 1×10 9 cfu / mL.

[0061] 1.2 Modeling and grouping

[0062] The experiment takes 28 days, with the adaptation period from 1 to 7 days, the modeling period from 8 to 14 days, and the intervention period from 15 to 28 days.

[0063] Adaptation: The animals used in the experiment were 40 5-week-old C57BL / 6 mice with a body weight of 18-25 g. Subsequent experiments were performed after 7 days of adaptation.

[0064] Modeling: Hyperuricemia modeling: Mice were gavaged at 9:00 a.m. daily with potassium oxonate-adenine-sodium hydroxymethylcellulose suspension. A standard dose of 250 mg / kg potassium oxonate and 100 mg / kg adenine was gavaged according to the mouse body weight for a total of 7 days to establish a hyperuricemia mouse model.

[0065] 40 mice were randomly divided into 4 groups: control group (Normal), model group, positive control group and treatment group. The mice in the model group, positive control group and treatment group were all subjected to hyperuricemia modeling. The control group was gavaged with 0.5% CMC-Na suspension on days 8-21, 0.2 mL per mouse per day.

[0066] Intervention period: All mice were gavaged at 9:00 every day. Control group: Normal mice were gavaged with 0.5% CMC-Na suspension, 0.2 mL per mouse per day; model group, positive control group and treatment group continued to be gavaged with potassium oxonate-adenine-CMC-Na suspension during the intervention period; at the same time, mice in the treatment group were gavaged with 0.2 mL (1×10 9 cfu / mL); mice in the positive control group were gavaged with allopurinol-CMC-Na suspension at a standard dose of 60 mg / kg body weight.

[0067] Sampling: After the intervention period, the mice in each group were fasted for 12 hours, anesthetized, and blood was collected by eyeball blood sampling. The blood was placed in a sterile blood collection tube, centrifuged at 3000rpm for 10 minutes, and the supernatant was temporarily stored in a 4°C refrigerator. It was used to determine the serum uric acid content of mice; after dissecting the mice, other tissues such as liver and kidney were quickly removed, frozen in liquid nitrogen to prevent tissue self-thawing, and stored in a -80°C refrigerator after aliquoting. The liver was used to determine the activity of mouse liver XOD, and the kidney was used for H&E staining analysis.

[0068] Mouse feces were collected and fecal DNA was extracted according to the instructions of the EZNA fecal DNA kit (Omega Bio-tek, USA). Universal primers were used to amplify the V3-V4 region of the bacterial 16S rRNA gene in feces. The primer sequences were:

[0069] 338F: 5'-ACTCCTACGGGAGGCAGCA-3';

[0070] 806R: 5'-GGACTACHVGGGTWTCTAAT-3'.

[0071] The amplified fragments were purified using a DNA extraction kit (Axygen Biosciences) and used to determine the intestinal flora.

[0072] 2. Serum uric acid determination

[0073] Take mouse serum and place it on an ice box. Prepare 50 mg / L uric acid standard application solution and prepare it immediately before use. Take 0.2 mL of mouse serum and 2 mL of tungstate protein precipitant, mix them, let stand for 10 minutes, centrifuge at 4°C, 3000 rpm / min for 5 minutes to obtain the supernatant. Take 1.6 mL of the supernatant and add 0.5 mL each of CUT reagent and phosphotungstic acid reagent, mix thoroughly in a centrifuge tube, and let stand for 10 minutes. After the reaction is completed, take 0.2 mL of the mixture in a 96-well plate and measure the OD 690 nm The absorbance is recorded as A determination. Use 50 mg / L uric acid standard application solution to replace serum, and the measurement result is A standard. Take ultrapure water to replace serum, and the measurement result is A blank.

[0074] The formula for calculating uric acid content is as follows:

[0075]

[0076] Wherein: C standard is the concentration of the standard, i.e. 50 mg / L.

[0077] Uric acid results Figure 1 As shown, compared with the control group, the serum uric acid level of mice in the model group was significantly increased. After intragastric administration of AR342 bacterial suspension, the serum uric acid concentration of mice decreased significantly, by 38.72%.

[0078] 3. Effect of AR342 on XOD activity in the liver of hyperuricemia mice

[0079] Liver XOD activity assay: Accurately weigh 0.1g of mouse liver and wash the blood with normal saline. Add 9 times the mass of homogenization medium (0.9% normal saline) to the mouse liver, mechanically homogenize, and prepare a 10% homogenate in an ice water bath. Use a refrigerated centrifuge at 3000rpm / min and 4°C for 10min. Take the supernatant into a centrifuge tube and place it on an ice box for later use. Take 20μL of liver homogenate to measure the activity of xanthine oxidase. Add reagents according to the instructions of the xanthine oxidase activity kit, mix well, and heat in a 37°C water bath for 20min. Add the stop solution and mix well. Take 200μL in a 96-well plate, adjust to zero with double distilled water, and OD 530 nm Measurement of XOD activity.

[0080] The results are as follows Figure 2 As shown, compared with the control group, the XOD activity in the liver of the mice in the model group was significantly increased, while after oral administration of AR342 bacterial suspension, the XOD activity in the liver of the mice was significantly decreased, decreasing by 32.67%.

[0081] Figure 3 H&E staining analysis of mouse kidneys showed that the kidneys of mice in the model group showed severe renal damage, with a large number of inflammatory cells, enlarged intercellular spaces, large vacuoles between tissues, necrosis and shedding of a small number of renal tubular epithelial cells, and severe twisting of some renal tubules, irregular shapes, and unclear boundaries. After intragastric administration of AR342 bacterial suspension, vacuoles and necrosis between renal tissues were significantly reduced, inflammation was significantly alleviated, tissue boundaries were clear, cell nuclei were obvious, and the effect of alleviating renal damage was obvious.

[0082] 4. Effect of AR342 on intestinal flora of hyperuricemia mice

[0083] The purified and amplified mouse fecal DNA fragments were sent to Shanghai Meiji Biopharmaceutical Technology Co., Ltd. for sequencing and data analysis. Figure 4 As shown in the figure, the intestinal flora of mice in the model group was significantly different from that in the control group. After oral administration of AR342 bacterial suspension, the composition of intestinal flora was improved, among which the abundance of beneficial bacterial genera such as Bifidobacterium and Akkermansia muciniphila was significantly increased.

[0084] Example 3 Pea polypeptide can alleviate hyperuricemia in mice

[0085] 1. Preparation of pea polypeptide (WPP)

[0086] Take pea crude protein (derived from the byproduct of pea starch production process, rich in protein and dietary fiber, the pea crude protein used in the present invention is a commercially available pea protein with a crude protein content of ≥80%, purchased from Zhengzhou Guangwang Biotechnology Co., Ltd.) 100g, mix the pea crude protein and sterile water in a ratio of 1:1 (m / v), and then inoculate Aspergillus oryzae BR88 (preserved in the General Microbiological Center of the China Microbiological Culture Collection Administration Committee on June 3, 2015, numbered CGMCC No.10950) in the pea crude protein for solid-state fermentation. The fermentation conditions are: the inoculation amount of Aspergillus oryzae is 10% (v / m), and the fermentation is carried out at 25°C for 30h. After the fermentation is completed, 3 times the mass of water is added for homogenization for 5 minutes, and the supernatant is collected by centrifugation at 8000rpm after the end, and ultrafiltration is continuously performed through membranes with molecular weights of 5000Da and 1000Da, respectively, and the filtrate after ultrafiltration is freeze-dried to obtain pea polypeptides.

[0087] 2. WPP alone treated hyperuricemia mice

[0088] The hyperuricemia mice were modeled according to the method described in Example 2. After the modeling was successful, the intervention period began and the mice were divided into the following groups: control group: normal mice were gavaged with 0.5% CMC-Na suspension, 0.2 mL per mouse per day; model group: hyperuricemia model mice were gavaged with potassium oxonate-adenine-CMC-Na suspension, and the standard doses of 250 mg / kg potassium oxonate and 100 mg / kg adenine were gavaged according to the body weight of the mice; WPP group: hyperuricemia model mice were gavaged with WPP (200 mg / kg body weight); positive control group: hyperuricemia model mice were gavaged with allopurinol-CMC-Na suspension, and the standard dose of 60 mg / kg body weight of the mice was gavaged.

[0089] The uric acid content in mouse serum was measured by the method described in Example 2. The results are as follows Figure 5 As shown, compared with the control group, the serum uric acid level of the mice in the model group was significantly increased, while after oral administration of pea polypeptide, the serum uric acid concentration of the mice decreased significantly, by 17.56%.

[0090] Example 4: Pea polypeptide and Lactobacillus plantarum AR342 synergistically treat hyperuricemia mice

[0091] 1. Preparation of a suspension of WPP and AR342:

[0092] Lactobacillus plantarum AR342 was re-dissolved in sterile water to prepare a bacterial suspension (1×10 9 cfu / mL), and then WPP powder was added to the bacterial suspension at a mass ratio of 1:1 with Lactobacillus plantarum AR342, and mixed evenly.

[0093] 2. WPP and AR342 synergistically treat hyperuricemia mice

[0094] The hyperuricemia mice were modeled according to the method described in Example 2. After the modeling was successful, the intervention period began and the mice were divided into the following groups: control group: normal mice were gavaged with 0.5% CMC-Na suspension, 0.2 mL per mouse per day; model group: hyperuricemia model mice were gavaged with potassium oxonate-adenine-CMC-Na suspension, and the standard dose of 250 mg / kg potassium oxonate and 100 mg / kg adenine was gavaged according to the weight of the mice; WPP group: hyperuricemia model mice were gavaged with WPP (200 mg / kg body weight); AR342 group: hyperuricemia model mice were gavaged with 0.2 mL of AR342 bacterial suspension (1×10 9 cfu / mL); synergistic intervention group: hyperuricemia model mice were gavaged with 0.2 mL of WPP and AR342 suspension; positive control group: hyperuricemia model mice were gavaged with allopurinol-CMC-Na suspension at a standard dose of 60 mg / kg body weight.

[0095] The uric acid content in mouse serum was measured by the method in Example 2. The results are as follows Figure 6 As shown in the figure, compared with the control group, the serum uric acid level of mice in the model group was significantly increased. The synergistic treatment effect of pea polypeptide WPP and Lactobacillus plantarum AR342 was the best, and was comparable to the effect of allopurinol. The serum uric acid concentration of mice in the synergistic treatment group was significantly lower than that of WPP or AR342 alone.

[0096] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A strain of Lactobacillus plantarum AR342, It is characterized in that The deposit number of the Lactobacillus plantarum AR342 is CGMCC No.27368.

2. A synergistic composition of pea polypeptide and Lactobacillus plantarum AR342, It is characterized in that The synergistic composition comprises pea polypeptide and Lactobacillus plantarum AR342 in a mass ratio of 1:1; The preservation number of the Lactobacillus plantarum AR342 is CGMCC No.27368; the pea polypeptide is obtained by fermenting pea crude protein.

3. A method for preparing the synergistic composition according to claim 2, It is characterized in that The method comprises the step of mixing pea polypeptide with plant lactobacillus AR342.

4. The preparation method according to claim 3, It is characterized in that The plant lactobacillus AR342 is mixed in the form of a bacterial suspension; the concentration of the plant lactobacillus AR342 bacterial suspension is 1×10 9 cfu / mL.

5. The preparation method according to claim 3, It is characterized in that The pea polypeptide is prepared by the following steps: After mixing pea crude protein and sterile water in a mass volume ratio of (1-2):(1-3), inoculating Aspergillus oryzae BR88 for solid-state fermentation; After the fermentation is completed, the slurry is homogenized and the supernatant is collected by centrifugation; The supernatant is ultrafiltered, and the filtrate is freeze-dried to obtain pea polypeptide.

6. The preparation method according to claim 5, It is characterized in that The deposit number of Aspergillus oryzae BR88 is CGMCC No.10950, and the inoculation amount is 5-15% v / m; The fermentation condition is 25° C. for 30 h.

7. The preparation method according to claim 5, It is characterized in that The homogenization treatment time is 5-10 minutes.

8. The preparation method according to claim 5, It is characterized in that The ultrafiltration is performed by continuously passing through 5000Da and 1000Da membranes.

9. Use of the synergistic composition according to claim 2 in the preparation of a drug for preventing and / or treating hyperuricemia.

10. A drug for preventing and treating hyperuricemia, It is characterized in that Comprising the synergistic composition of claim 2.

Images